US Pharm. 2012;37(6):50-56.
Hypoglycemia is a low concentration of glucose in the blood, but no specific plasma glucose level defines the condition.1 Rather, hypoglycemia is best described as a plasma glucose concentration sufficiently low to elicit signs and/or symptoms.1
In healthy individuals, the glycemic threshold for symptoms is 50 to 55
mg/dL, although plasma glucose levels under 70 mg/dL signal impending
hypoglycemia.2 Symptoms can occur at higher concentrations in
patients with poorly controlled diabetes, and at lower levels in those
with tight glycemic control or recent hypoglycemic exposure.2 Most hypoglycemia is iatrogenic and associated with drug-treated diabetes mellitus.1 Other causes of hypoglycemia, rare in individuals older than 10 years of age, will be briefly discussed later.
Glucose supplies immediate energy needs and fuels metabolic functions
between meals. If it is not needed for immediate use, glucose is stored
as glycogen in the liver and muscles, or else as fat.3
Glucose is a requisite metabolic fuel for brain cells. Because the brain
can neither synthesize glucose nor store more than a few minutes’
supply in the form of glycogen, it is critically important that a steady
glucose supply be available to brain cells via the circulation.2
In healthy individuals, a finely choreographed interaction between
insulin and several counterregulatory hormones, including glucagon,
epinephrine, cortisol, and growth hormone, ensures that blood glucose
concentrations are maintained within the physiological range. This
process is called glucose counterregulation. As plasma glucose
concentrations drop below physiological range, insulin secretion
decreases and ultimately ceases. Glucagon and epinephrine concentrations
increase concurrently to produce a rapid rise in plasma glucose, thus
averting or swiftly correcting hypoglycemia.2 Glucagon
stimulates glycogenolysis (the breakdown of glycogen into glucose) in
the liver, as well as hepatic gluconeogenesis (the formation of glucose
from noncarbohydrate substrates). Epinephrine promotes hepatic
glycogenolysis and hepatic and renal gluconeogenesis. Cortisol and
growth hormone work slowly over hours to defend against prolonged
hypoglycemia, but they play a minimal role in reversing hypoglycemia.1
HYPOGLYCEMIA IN PATIENTS WITH DIABETES
The goal of diabetes management is a lifetime of euglycemia without hypoglycemia.4
Hypoglycemia constitutes a significant roadblock to achieving both
short-term and long-term glycemic control, which may lead to the
development of long-term complications of diabetes.2 It is
estimated that, on average, individuals with type 1 diabetes mellitus
(T1DM) experience two symptomatic episodes of hypoglycemia weekly and
one severe event annually. With declining pancreatic function, the
incidence of hypoglycemia increases in type 2 diabetes mellitus (T2DM).2
The negative effects of hypoglycemia include psychological morbidity,
physical morbidity, and mortality. In patients with diabetes, the fear
of hypoglycemia exceeds the fear of long-term complications.2
In T1DM and advanced T2DM, glucose counterregulation is compromised
by the impaired secretion of insulin, glucagon, and epinephrine,
breaching three physiological defenses against hypoglycemia. First,
falling plasma glucose concentrations fail to elicit a corresponding
decrease in insulin secretion in patients taking insulin or insulin
secretagogues. With absolute or relative exogenous insulin excess,
insulin activity is dictated by the pharmacokinetic characteristics of
the drug. Second, hypoglycemia does not trigger glucagon secretion.
Third, a lower plasma glucose concentration is required to stimulate an
Some patients with T1DM or advanced T2DM lose the neurogenic warning symptoms that herald impending hypoglycemia. This state, hypoglycemia unawareness,
is likely the result of repeated iatrogenic hypoglycemia episodes that
lead to impaired epinephrine response and diminished neurogenic
symptoms.2 The weakened counterregulatory response, hypoglycemia-associated autonomic failure
(HAAF), puts the patient at high risk for severe hypoglycemia.
Fortunately, a 2- to 3-week period of strict avoidance of hypoglycemia
appears to improve the epinephrine response and restore hypoglycemia
Causes and Risk Factors
Iatrogenic hypoglycemia results from therapy that raises insulin concentrations and lowers plasma glucose concentrations.1
Agents include insulin and insulin secretagogues. Other diabetes drugs
may cause hypoglycemia when combined with insulin or insulin
secretagogues (TABLE 1).
Conventional risk factors for iatrogenic hypoglycemia relate to relative or absolute insulin excess (FIGURE 1).
As discussed previously, HAAF is associated with a high risk of
hypoglycemia. Risk factors include an absolute deficiency of endogenous
insulin; a history of severe hypoglycemia and/or hypoglycemia
unawareness, as well as recent hypoglycemia, prior exercise, and sleep;
and intensive glycemic therapy as evidenced by lower glycosylated
hemoglobin concentrations and/or lower glycemic goals.1
Symptoms of Hypoglycemia
A reduction in blood glucose initiates an autonomic nervous system
response, resulting in neurogenic signs and symptoms (categorized as
adrenergic or cholinergic) that alert the patient to a hypoglycemic
episode (TABLE 2). Each patient’s array of symptoms is unique and
may vary in magnitude over time. However, signs and symptoms often
present in diabetes are also frequently associated with other disease
states, and hypoglycemia does not necessarily elicit these signs and
symptoms. Thus, hypoglycemia is best confirmed by Whipple’s triad:
symptoms consistent with hypoglycemia, a low plasma glucose
concentration, and symptom relief when the glucose concentration is
raised.4 Optimally, the presence of signs and symptoms during
mild hypoglycemia prompts the patient to ingest carbohydrates, thereby
enabling blood glucose concentrations to normalize. If the episode
progresses, the deficiency of glucose in brain cells results in
neuroglycopenic symptoms. Lack of attention to mild symptoms or
compromised autonomic response signals may preclude recognition of a
hypoglycemic event. The pharmacist should counsel the patient to be
attentive to symptoms, self-monitor blood glucose (SMBG) whenever
suspicious, and treat for hypoglycemia if monitoring is not available.2
It is estimated that more than 50% of hypoglycemic episodes occur during sleep, and the sufferer usually is unaware of them.4
An individual might assume the occurrence of hypoglycemia if he or she
awakens with bedclothes damp with sweat and is confused, irritated, or
tired, or was calling out or having nightmares during sleep.3
In such cases, periodic 3-AM SMBG is recommended to determine whether
hypoglycemia is occurring overnight. Nighttime hypoglycemia is suspected
of causing arrhythmias that lead to unforeseen death, or dead-in-bed syndrome.1
Treatment of Mild-to-Moderate Hypoglycemia
When hypoglycemia is suspected, SMBG should be performed if a meter
is available. A reading below 70 mg/dL indicates the need for immediate
consumption of 15 to 20 g of simple carbohydrates, preferably glucose.5
If testing is not possible, remember: “When in doubt, treat.” Untreated
hypoglycemia presents a greater risk than that posed by an episode of
hyperglycemia. Severe and protracted neuroglycopenia, although rare, may
lead to permanent brain damage and even death.2 Recommended
carbohydrates include 3 to 4 glucose tablets (5 g each); 1 tube of
glucose gel; 4 oz. fruit juice or soft drink (not sugar free); 8 oz.
milk (low-fat preferred); 4 to 6 pieces of hard candy (not sugar free);
or 1 tbsp. sugar, honey, or corn syrup. Protein does not impair the
desired glycemic response, but fat does. Therefore, chocolate candy is
not recommended unless no other simple carbohydrate is available.
Blood glucose should be rechecked at 15-minute intervals, and
treatment repeated if glucose remains below 70 mg/dL. Once blood glucose
is at or above 70 mg/dL, the patient should eat a snack or meal to
Treatment of Severe Hypoglycemia
Neuroglycopenia can impair an individual to the extent that someone
else must administer treatment. If the patient can safely swallow,
glucose gel, honey, jelly, or syrup should be placed inside the cheek
for absorption. If the patient is unable to swallow or is unconscious, a
glucagon injection is required to rapidly elevate the serum glucose
level.3 IV dextrose is the preferred treatment for
hospitalized patients. Once conscious, the patient should drink a
carbohydrate-rich fluid, followed by a snack once he or she is no longer
nauseated. Medical supervision is indicated until the risk of recurrent
hypoglycemia has passed.2
A prudent pharmacist counsels patients with diabetes on hypoglycemia avoidance during each contact.1
Patients should follow a diabetes management plan that includes blood
glucose monitoring (with scrupulous monitoring when ill), a medication
protocol, meal and snack planning, management of activity and exercise,
and moderate alcohol ingestion.3
The patient should be reminded that diabetes medication may need to
be adjusted to respond to changes in food ingestion and physical
activity. The pharmacist should ascertain that the patient knows how to
use his or her meter, and should suggest alternative solutions if
medications or meter supplies are a financial hardship. Information on
medications that are more likely to cause hypoglycemia should be
provided, and patients taking acarbose or miglitol should be cautioned
that only dextrose will raise blood glucose during a hypoglycemic
episode.3 The pharmacist should offer glucagon emergency kit
training to the patient’s family members. The patient should be reminded
to carry a simple carbohydrate source—preferably glucose tablets—at all
times and to avoid the accidental consumption of sugar-free candy or
soft drinks in the treatment of hypoglycemia. The patient should be
advised to perform SMBG before driving if he or she is at risk for
hypoglycemia, to test often during long driving trips, and to refrain
from driving until blood glucose is at least 70 mg/dL.3 The
pharmacist must recognize that information and willingness to follow a
diabetes management plan are essential for enabling a patient to avoid
hypoglycemia and live successfully with diabetes.2
Hypoglycemia can occur in those not being treated for diabetes.
Organizations such as the National Institutes of Health and the National
Diabetes Information Clearinghouse note the existence of several types
of noniatrogenic hypoglycemia.
Reactive (Postprandial) Hypoglycemia
Reactive hypoglycemia occurs within 4 hours after a meal is consumed, with diagnosis based on documentation of Whipple’s triad.1,3
Several causes have been proposed but are unsubstantiated, including
excessive release of insulin following high sugar intake, enhanced
sensitivity to the normal secretion of epinephrine and its attendant
hypoglycemic symptoms, and deficient glucagon secretion.3
Gastrointestinal surgery can cause hypoglycemia if food passes into
the small intestine too quickly, but this is uncommon. Rare hereditary
enzyme deficiencies can lead to fructose intolerance and reactive
Fasting (Postabsorptive) Hypoglycemia
This condition may be diagnosed when the serum glucose concentration
is below 50 mg/dL after overnight fasting, between meals, or following
physical activity.3 Several underlying conditions can
contribute to fasting hypoglycemia, including the consumption of
medications other than those used to treat diabetes (TABLE 3).
Alcohol consumption, especially binge drinking, can cause severe or even
fatal hypoglycemia by halting gluconeogenesis and depleting hepatic
glycogen.6 Critical illnesses affecting the liver, heart, or kidneys can contribute to fasting hypoglycemia.3 Sepsis can deplete hepatic glycogen stores and impair gluconeogenesis.7 Disorders involving renal insufficiency can decrease drug elimination and affect serum glucose concentration.8
Starvation conditions (e.g., anorexia nervosa) can deplete glycogen and
fat stores used for energy between meals, as well as substrates used in
Treatment of the underlying cause will help resolve hypoglycemia.
Deficiencies of glucagon, epinephrine, cortisol, and growth hormone,
which are rare, are usually corrected by exogenous hormone
supplementation.3 Such conditions are more common in
very young children than in adults. Insulinomas—rare, usually benign
pancreatic tumors that secrete excessive amounts of insulin—can cause
hypoglycemia.1,3 Surgical removal of the insulinoma is
preferred, but pharmacologic agents such as diazoxide or octreotide also
may be used to lower serum insulin concentrations.
Hypoglycemic episodes compromise wellness in all who experience them.
In diabetic patients, the risk of hypoglycemia may limit the potential
for lifelong euglycemia.2,4 Pharmacists who offer education
and support afford their patients the opportunity to better understand
and follow their disease-management plans and to enjoy better health.
1. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management
of adult hypoglycemic disorders: an Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2009;94:709-728.
2. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
3. National Diabetes Information Clearinghouse. Hypoglycemia.
October 6, 2011.
4. American Diabetes Association. Defining and reporting hypoglycemia
in diabetes: a report from the American Diabetes Association Workgroup
on Hypoglycemia. Diabetes Care. 2005;28:1245-1249.
5. American Diabetes Association. Executive summary: standards of medical care in diabetes—2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
6. Masharani U. Diabetes mellitus and hypoglycemia. In: McPhee SJ, Papadakis MA, Rabow MW, eds. CURRENT Medical Diagnosis and Treatment 2012. 51st ed. New York, NY: McGraw-Hill Medical; 2011.
7. Miller SI, Wallace RJ Jr, Musher DM, et al. Hypoglycemia as a manifestation of sepsis. Am J Med. 1980;68:649-654.
8. Mayo Clinic. Hypoglycemia. Causes. www.mayoclinic.com/health/hypoglycemia/DS00198/DSECTION=causes. Accessed March 27, 2012.
9. Thomson Reuters Micromedex 2.0. www.micromedex.com. Accessed March 25, 2012.
10. Vue MH, Setter SM. Drug-induced glucose alterations part 1: drug-induced hypoglycemia. Diabetes Spectrum. 2011;24:171-177.
11. MedlinePlus. Drug-induced hypoglycemia. www.nlm.nih.gov/medlineplus/ency/article/000310.htm. Accessed March 25, 2012.
12. CDC. Treatment of malaria (guidelines for clinicians).
www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf. Accessed May 1,
13. Kojak G Jr, Barry MJ Jr, Gastineau CF. Severe hypoglycemic reaction with haloperidol: report of a case. Am J Psychiatry. 1969;126:573-576.
14. Walter RB, Hoofnagle AN, Lanum SA, Collins SJ. Acute,
life-threatening hypoglycemia associated with haloperidol in a
hematopoietic stem cell transplant recipient [letter]. Bone Marrow Transplant. 2006;37:109-110.
To comment on this article, contact email@example.com.